Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

Function Health / Private Capital Markets

<ul><li>Sacra estimates Function Health grew to a $100M revenue run rate in February 2025, up 450% year-over-year with approximately 200,000 subscribers.</li><li>Function Health is a $100M/year consumer blood testing startup offering a $499/year subscription for comprehensive blood testing—now expanding into imaging and genomics as it builds a unified platform for self-directed health tracking.</li><li>Moving beyond blood testing, Function Health’s acquisition of Ezra (May 2025) has it bundling full-body MRI scanning into its membership product at $499/scan (down from $1,495 pre-acquisition), expanding its product surface area as pure-play blood testing is commoditized.</li></ul>

Sacra estimates Function Health grew to a $100M revenue run rate in February 2025, up 450% year-over-year with approximately 200,000 subscribers.Function Health is a $100M/year consumer blood testing startup offering a $499/year subscription for comprehensive blood testing—now expanding into imaging and genomics as it builds a unified platform for self-directed health tracking.Moving beyond blood testing, Function Health’s acquisition of Ezra (May 2025) has it bundling full-body MRI scanning into its membership product at $499/scan (down from $1,495 pre-acquisition), expanding its product surface area as pure-play blood testing is commoditized.

<ul><li>Maven Clinic will hit $268M of ARR in 2024, up 26% YoY, with their women’s health benefit offering now covering 17 million people globally.</li><li>After doubling down on fertility, Maven has now won their biggest customer ever in Amazon, who switched away from incumbent Progyny (NASDAQ: PGNY) for 2025.</li><li>Maven's asset-light model combining coaching, content and telehealth has enabled them to go global (175 countries)—without sacrificing retention (98% customer retention).</li></ul>

Maven Clinic will hit $268M of ARR in 2024, up 26% YoY, with their women’s health benefit offering now covering 17 million people globally.After doubling down on fertility, Maven has now won their biggest customer ever in Amazon, who switched away from incumbent Progyny (NASDAQ: PGNY) for 2025.Maven's asset-light model combining coaching, content and telehealth has enabled them to go global (175 countries)—without sacrificing retention (98% customer retention).

United States

Telehealth benefit for employers offering fertility, maternity, pediatrics, and menopause care

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Maven Clinic (CLINIC US)

Function Health At $100M/year

TL;DR: With the rise of consumer interest in longevity and health optimization, Function Health is building a $499/year bundle for 100+ biomarker...

Sacra

Maven Clinic At $268M ARR

TL;DR: Sacra estimates that Maven Clinic will hit $268M of ARR in 2024, up 26% YoY, with their women’s health benefit offering now covering 17...

Sacra

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)